Back to discover

Drug

Respiratory Syncytial Virus Vaccines

Research stage

Emerging research

1

Research papers

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

Research2018-04-01The Journal of infectious diseases

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Respiratory Syncytial Virus Vaccines

RxNorm CUI

2672856

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

The Journal of infectious diseases · 2018 · 35 cites

Recent papers

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

The Journal of infectious diseases · 2018 · 35 cites

Journals, researchers & institutions

Top journals

The Journal of infectious diseases1

Leading researchers

Beran J1
Chu L1
David MP1
Dieussaert I1
Domachowske JB1
Fissette LA1
Johnson C1
Lickliter JD1

Leading institutions

free-text, unnormalised

Clinical Research and Development1
Johnson County Clinic Trials1
SUNY Upstate Medical Center1
Vaccination and Travel Medicine Centre1
Vaccine and Infectious Disease Institute1

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
Europe PMC — research literature